McKesson (MCK)
(Delayed Data from NYSE)
$485.42 USD
+3.15 (0.65%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$485.42 USD
+3.15 (0.65%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
McKesson (MCK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed the most recent trading day at $307.68, moving +0.38% from the previous trading session.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
McKesson (MCK) Stock Moves -0.95%: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed at $312.03 in the latest trading session, marking a -0.95% move from the prior day.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXG
Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?
by Zacks Equity Research
Sector ETF report for FXG
5 Stocks in S&P 500 ETF Defying Losing Streak Since 2011
by Sweta Killa
While most of the stocks in SPY's portfolio are deep in red, a few have outperformed so far this year, with energy stocks being the biggest gainers.
McKesson (MCK) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2022 results benefit from segmental growth.
McKesson (MCK) Lags Q4 Earnings Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of -3.80% and 3.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stocks' Earnings May 5 Roster: MCK, CAH & PODD
by Debanjana Dey
The Medical Product companies' quarterly results are likely to reflect base business recovery. Let's see how MCK, CAH and PODD are poised ahead of their earnings releases.
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CLRG
McKesson (MCK) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson (MCK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed the most recent trading day at $317.31, moving -0.27% from the previous trading session.
Is IQ Chaikin U.S. Large Cap ETF (CLRG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CLRG
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Illumina (ILMN) Hurt by Rising Costs, Tough Competition
by Zacks Equity Research
Regulatory complications are raising the legal expenses for Illumina (ILMN), thereby building pressure on the bottom line.
Here's Why You Should Retain Phibro (PAHC) Stock For Now
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC) owing to the robust performances by its Animal Health and Mineral Health segments.
Integer Holdings' (ITGR) Latest Buyout to Expand Its Footprint
by Zacks Equity Research
Integer Holdings' (ITGR) buyout of Aran Biomedical is set to expand its presence in high-growth markets as well as enhance its product offerings.
Masimo's (MASI) Sound United Buyout to Boost Product Portfolio
by Zacks Equity Research
Masimo's (MASI) completion of Sound United's buyout to help enhance the former's extended portfolio of hospital and home medical technology solutions.
Illumina (ILMN) Launches Genomic Solution Hub in Brazil
by Zacks Equity Research
Illumina's (ILMN) customers and partners in Brazil currently span basic research, applied markets to clinical labs and healthcare institutions.
NEOGEN (NEOG) Adds to Prozap Insect Control Product Line-up
by Zacks Equity Research
NEOGEN's (NEOG) latest Prozap Protectus Pour-On Insecticide- IGR product relieves cattle from infestations.
Here's Why You Should Hold on to Cardiovascular Systems (CSII)
by Zacks Equity Research
Investors are optimistic about Cardiovascular Systems' (CSII) robust international growth and upcoming launches.
Here's Why You Should Retain SmileDirectClub (SDC) For Now
by Zacks Equity Research
Investors are optimistic about SmileDirectClub's (SDC) series of cutting-edge innovation, strategic distribution and insurance partnerships.
Bruker (BRKR) Unveils New Imaging Tools for Cancer Research
by Zacks Equity Research
Bruker's (BRKR) latest innovation for cancer research is likely to strengthen the company's opportunities in proteomics and spatial biology.